MedTrace Logo

Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication

NCT00424281 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2007-01-19

No results posted yet for this study

Summary

Patients in intensive care units have higher risks for developing blood clots. Arixtra inhibits blood clot formation by binding with the blood clotting factor, Xa. Critical illnesses and, specifically, medications given in the ICU to increase arterial blood pressure (vasopressors) may impair the absorption of drugs like Arixtra that are given subcutaneously. The study will measure the levels of Arixtra in blood comparing those subjects who are and those subjects who are not on blood pressure medication.

Conditions

  • ICU Patients 18 Years or Older.

Interventions

DRUG

Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability

Sponsors & Collaborators

Principal Investigators

  • M. Safwan Badr, MD · Wayne State University, Division of Pulmonary, Asthma, Critical Care, and Sleep Medicine

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00424281 on ClinicalTrials.gov